Next Article in Journal
Systematic Review and Pragmatic Clinical Approach to Oral and Nasal Vitamin B12 (Cobalamin) Treatment in Patients with Vitamin B12 Deficiency Related to Gastrointestinal Disorders
Next Article in Special Issue
Low TIP30 Protein Expression is Associated with a High Risk of Metastasis and Poor Prognosis for Non-Small-Cell Lung Cancer
Previous Article in Journal
Examining Young Children’s Physical Activity and Sedentary Behaviors in an Exergaming Program Using Accelerometry
Previous Article in Special Issue
Targeted Molecular Treatments in Non-Small Cell Lung Cancer: A Clinical Guide for Oncologists
Open AccessReview

CXCR4 Based Therapeutics for Non-Small Cell Lung Cancer (NSCLC)

by 1,2
1
Department of Cardiothoracic Surgery, Hadassah Hebrew University Hospital, Jerusalem 91120, Israel
2
Goldyne Savad Institute of Gene Therapy, Hadassah Hebrew University Hospital, Jerusalem 91120, Israel
J. Clin. Med. 2018, 7(10), 303; https://doi.org/10.3390/jcm7100303
Received: 12 August 2018 / Revised: 16 September 2018 / Accepted: 23 September 2018 / Published: 25 September 2018
Lung cancer is the second most common malignancy. Unfortunately, despite advances in multimodality therapeutics for the disease, the overall five-year survival rate among newly diagnosed lung cancer patients remains in the range region of 15%. In addition, although immune checkpoint inhibitors are increasingly being incorporated into lung cancer treatment protocols, the proportion of patients that respond to these agents remains low and the duration of response is often short. Therefore, novel methodologies to enhance the efficacy of immunotherapy in lung cancer are highly desirable. Chemokines are small chemotactic cytokines that interact with their 7 transmembrane G-protein–coupled receptors, to guide immune cell trafficking in the body under both physiologic and pathologic conditions. Tumor cells highjack a small repertoire of the chemokine/chemokine receptor system and utilize it in a manner that benefits local tumor growth and distant spread. The chemokine receptor, CXCR4 is expressed in over 30 types of malignant tumors and, through interaction with its ligand CXCL12, was shown exert pleotropic pro-tumorigenic effects. In this review, the pathologic roles that CXCL12/CXCR4 play in lung cancer propagation are presented. Furthermore, the challenges and potential benefits of incorporating drugs that target CXCL12/CXCR4 into immune-based lung cancer therapeutic protocols are discussed. View Full-Text
Keywords: NSCLC; lung; chemokines; immune checkpoint inhibitors NSCLC; lung; chemokines; immune checkpoint inhibitors
MDPI and ACS Style

Wald, O. CXCR4 Based Therapeutics for Non-Small Cell Lung Cancer (NSCLC). J. Clin. Med. 2018, 7, 303. https://doi.org/10.3390/jcm7100303

AMA Style

Wald O. CXCR4 Based Therapeutics for Non-Small Cell Lung Cancer (NSCLC). Journal of Clinical Medicine. 2018; 7(10):303. https://doi.org/10.3390/jcm7100303

Chicago/Turabian Style

Wald, Ori. 2018. "CXCR4 Based Therapeutics for Non-Small Cell Lung Cancer (NSCLC)" J. Clin. Med. 7, no. 10: 303. https://doi.org/10.3390/jcm7100303

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop